## Accepted Manuscript

Title: Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation

Authors: Erika Cecchin, Elena De Mattia, Fabrizio Ecca, Giuseppe Toffoli



| PII:           | S1368-7646(18)30036-0                      |
|----------------|--|
| DOI:           | https://doi.org/10.1016/j.drup.2018.07.001 |
| Reference:     | YDRUP 623                                  |
| To appear in:  | Drug Resistance Updates                    |
| Received date: | 28-2-2018                                  |
| Revised date:  | 11-6-2018                                  |
| Accepted date: | 6-7-2018                                   |

Please cite this article as: Cecchin E, De Mattia E, Ecca F, Toffoli G, Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation, *Drug Resistance Updates* (2018), https://doi.org/10.1016/j.drup.2018.07.001

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# ACCEPTED MANUSCRIPT

#### Title

Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation

Running Title: Pharmacogenetics and drug safety

Authors: Erika Cecchin<sup>1</sup>, Elena De Mattia<sup>1</sup>, Fabrizio Ecca<sup>1</sup> and Giuseppe Toffoli<sup>1\*</sup>

<sup>1</sup>Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico – National Cancer Institute, 33081 Aviano, Italy.

#### **Correspondence to:**

\*Dr. Giuseppe Toffoli MD, Director, Clinical and Experimental Pharmacology, CRO-National Cancer Institute, Via Franco Gallini n. 2, 33081 Aviano (PN) –Italy. gtoffoli@cro.it Telephone +39-0434-659612 and Fax +39-0434-659799

### ABSTRACT

Adverse events affect the pharmacological treatment of approximately 90% of colorectal cancer (CRC) patients at any stage of the disease. Chemotherapy including fluoropyrimidines, irinotecan, and oxaliplatin is the cornerstone of the pharmacological treatment of CRC. The introduction of novel targeted agents, as anti-EGFR (i.e. cetuximab, panitumumab) and antiangiogenic (i.e. bevacizumab, ziv-aflibercept, regorafenib, and

Download English Version:

https://daneshyari.com/en/article/8436425

Download Persian Version:

https://daneshyari.com/article/8436425

Daneshyari.com